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An alarming increase in bacteria with resistance to various antibiotics has been
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Purpose: Antimicrobial resistance monitoring could be a useful source of infor-
mation for treating and controlling nosocomial infections. We analyzed antimi-
crobial resistance data generated by Korean Hospitals and by a commercial
laboratory in 2005 and 2007. Materials and Methods: Susceptibility data for
2005 and 2007 were collected from 37 and 41 hospitals, respectively, and from
one commercial laboratory. Intermediate susceptibility was not included in the
calculation of resistance rates. Results: Methicillin-resistant Staphylococcus
aureus (MRSA) (64%), third-generation cephalosporin-resistant Klebsiella
pneumoniae (29%), fluoroquinolone-resistant Escherichia coli (27%), Pseu-
domonas aeruginosa (33%), and Acinetobacter spp. (48%), and amikacin-resistant
P. aeruginosa (19%) and Acinetobacter spp. (37%) were prevalent in hospitals in
2007. A gradual increase of vancomycin-resistant Enterococcus faecium and
imipenem-resistant Acinetobacter spp. was observed. Higher incidences of third-
generation cephalosporin-resistant E. coli and K. pneumoniae and imipenem-
resistant P. aeruginosa were found in the commercial laboratory than in the
hospitals. Conclusion: Methicillin-resistant S. aureus, third-generation cephalo-
sporin-resistant K. pneumoniae, and fluoroquinolone-resistant E. coli, P. aeru-
ginosa and Acinetobacter spp. remain prevalent in Korea, while the incidence of
vancomycin-resistant E. faecium and imipenem-resistant Acinetobacter spp. has
increased gradually. The higher prevalences of third-generation cephalosporin-
resistant E. coli and K. pneumoniae, and imipenem-resistant P. aeruginosa in the
commercial laboratory are a new concern.
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reported in many parts of the world. However, the pre-
valence of antibiotic-resistant bacteria varies greatly from
country to country, because it is influenced by antimi-
crobial usage and the spread of antibiotic resistance. With
the increased incidence of antibiotic-resistant bacteria,
optimal treatment of infected patients is often possible only
by detection of the etiologic organism and determination of
its susceptibility to various antibiotics. However, isolation
of the infecting organism is not always feasible, and even if
it is possible, results are not promptly accessible. Con-
sequently, initial antibiotic therapy is generally empirical.
The appropriate antibiotics can be empirically selected only
with the full knowledge of the current regional resistance
pattern.1 Antimicrobial resistance surveillance serves as a
fundamental basis for appreciating trends in resistance, de-
veloping accurate treatment guidelines, and evaluating the
efficacy of interventions (www.who.int/drugresistance/en/).
Monitoring the temporal patterns of resistance is an essential
element in the detection of subtle variations in antimi-
crobial resistance.2
Trends in antimicrobial resistance are most accurately
predicted by collecting clinical isolates and testing their
susceptibilities at a reference laboratory. This approach has
some drawbacks, however: the number of characterized
isolates is limited, and is costly. One example of this ap-
proach is the SENTRY program.1 Another frequently used
surveillance method is the analysis of routine susceptibility
test data from clinical laboratories. This approach has
inherent inaccuracies, because not all laboratories use the
same methods, but it has the advantage of not requiring
extensive resources.3,4 Based on a WHO recommendation,
the KONSAR program was initiated in 1997.5 Two surveil-
lance methods are employed in the KONSAR program:
annual analysis of test data generated by the participant
laboratories6 and the testing of problematic organisms col-
lected by the coordinating laboratory.7
Some of the most disturbing resistance trends found in the
first program were high incidences of methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus faecium, and increases in the prevalence of
third-generation cephalosporin-resistant Klebsiella pneumo-
niae and imipenem-resistant Pseudomonas aeruginosa and
Acinetobacter spp. Some of these particular antibiotic-
resistant organisms were also found to be prevalent by a
commercial laboratory (ComLab).6 The second program
revealed wide dissemination of metallo-β-lactamase (MBL)-
producing Pseudomonas spp. and Acinetobacter spp.,8,9
and a rapid increase in OXA carbapenemase-producing
Acinetobacter baumannii,9 as well as plasmid-mediated
AmpC enzyme-producing Escherichia coli and K. pneumo-
niae.10 For this study, we compared the rank order of orga-
nisms and resistance rates in hospitals and in a ComLab. 
Susceptibility data for 2005 and 2007 were collected from
37 and 41 hospitals, respectively, and from one ComLab.
The KONSAR program participating hospitals have their
own laboratories, whereas the ComLab in Seoul mostly
tests specimens from smaller hospitals or clinics without
in-house microbiology service. Of these, data from 18 and
23 hospitals, respectively, were excluded from the analysis
because the data contained multiple isolates from a single
patient. 
In previous surveillance studies, dividing the hospitals
into three groups according to location and bed capacity
did not result in a significant difference in resistance rates.
Therefore, all hospitals were grouped together in the
present analysis. The test data obtained at the ComLab
were analyzed separately. Intermediate susceptibility was
not included in the calculation of resistance rates as was in
the previous studies. For Streptococcus pneumoniae, the
penicillin G breakpoint of meningitis was used, although
most of the isolates were from other sites. If less than ten
isolates of an organism in a hospital were reported, the orga-
nism was not included in the calculation of mean rates to
avoid biasing these rates.11,12 Statistical significance of resis-
tance rates was not analyzed in this surveillance, as it was
considered difficult,13 and as it was the common practice in
the large scale and continuous surveillance program.14,15
Rank order of organisms and antimicrobial agents 
used for testing
In 2007, E. coli ranked No. 1 in terms of the most prevalent
organism isolated in both hospitals and the ComLab (19.3%
and 27.1%)(Table 1). The second most prevalent organism
was S. aureus in hospitals (17.8%) and P. aeruginosa in
the ComLab (17.5%). The organisms ranked No. 3 thro-
ugh No. 5 in hospitals were coagulase-negative staphylo-
cocci (CNS)(13.1%), P. aeruginosa (11.7%), and K. pneu-
moniae (10.0%), whereas in the ComLab, these organisms
were S. aureus (11.9%), K. pneumoniae (11.9%), and E.
faecalis (8.4%). Changes in the rank of prevalent organisms
in hospitals since 1998 were as follows: E. faecium from
No. 10 (2.4%) to No. 7 (6.2%), and Acineto-bacter spp.
from No. 5 (9.5%) to No. 8 (5.3%).
The appropriateness of antimicrobial agents used to test
susceptibility was analyzed for E. coli and S. aureus as
representatives of Gram-negative bacilli and Gram-positive
cocci, respectively. Overall, more hospitals followed the
CLSI guidelines in 2007 than in 2002. However, the pro-
MATERIALS AND METHODS
RESULTS
portions of hospitals that used cephalothin, cefoxitin,
ampicillin-sulbactam or amoxicillin-clavulanic acid, and
cotrimoxazole to test the susceptibility of E. coli were only
86%, 81%, 65%, and 51%, respectively (data not shown).
All hospitals used penicillin G, oxacillin (or cefoxitin to
screen MRSA), erythromycin, and clindamycin to test the
susceptibilities of S. aureus, but only 61% of hospitals
used cotrimoxazole.  
Resistances in the hospitals and in the ComLab 
Surveillance results for both 2005 and 2007 (Tables 2-5)
were analyzed in this study, but for simplicity, only the
results for 2007 are described. Of the S. aureus hospital
isolates, 64% and 8% were resistant to oxacillin (or to cefox-
itin for MRSA detection) and to cotrimoxazole, respectively
(Table 2). In the ComLab, 63% and 56% of S. aureus isola-
tes were resistant to oxacillin and clindamycin, respectively.
The resistance rates of CNS in hospitals to oxacillin and
clindamycin were 64% and 29%, respectively, whereas the
respective rates in the ComLab were 70% and 30%. 
In the hospitals, when the meningitis breakpoint was
applied, 69% of S. pneumoniae were nonsusceptible to
oxacillin, suggesting penicillin nonsusceptibility (Table 3).
The resistance of E. faecalis isolates to ampicillin and
KONSAR Surveillance Study 2005 and 2007
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Table 1. Comparison of the Number, Proportion, and Rank Order of Organisms Detected in Surveillance Programs in 1998, 
2004, and 2007 
Hospitals Commercial laboratory
Organism
1998 2004 2007 2007
No. (%) of Rank No. (%) of Rank No. (%) of Rank No. (%) of Rank 
isolates order isolates order isolates order isolates order
Escherichia coli 20,604 (16.5) 2 41,925 (17.7) 2 15,690 (19.3) 1 13,596 (27.1) 1
Klebsiella pneumoniae 9,079 (7.2) 6 25,320 (10.7) 5 8,117 (10.0) 5 5,955 (11.9) 4
Enterobacter cloacae 5,781 (4.6) 8 7,854 (3.3) 9 2,817 (3.5) 9 1,319 (2.6) 10
Serratia marcescens 3,324 (2.7) 9 5,743 (2.4) 10 1,956 (2.4) 10 2,604 (5.2) 7
Nontyphoidal Salmonella 962 (0.7) 12 545 (0.2) 13 401 (0.5) 12 241 (0.5) 12
Acinetobacter spp. 11,866 (9.5) 5 15,338 (6.5) 6 4,283 (5.3) 8 2,815 (5.6) 6
Pseudomonas aeruginosa 20,370 (16.3) 3 31,544 (13.3) 3 9,532 (11.7) 4 8,808 (17.5) 2
Haemophilus influenzae 746 (0.6) 13 954 (0.4) 12 337 (0.4) 13 164 (0.3) 13
Staphylococcus aureus 26,042 (20.9) 1 47,823 (20.2) 1 14,479 (17.8) 2 5,995 (11.9) 3
Coag.-Neg. staphylococci 13,854 (11.1) 4 28,809 (12.1) 4 10,612 (13.1) 3 2,216 (4.4) 8
Enterococcus faecalis 7,075 (5.7) 7 14,795 (6.2) 7 5,959 (7.3) 6 4,201 (8.4) 5
E. faecium 2,968 (2.4) 10 13,211 (5.6) 8 5,286 (6.2) 7 376 (2.7) 10
Streptococcus pneumoniae 2,187 (1.8) 11 3,297 (1.4) 11 1,818 (2.2) 11 743 (1.5) 11
Total 124,858 (100) 237,158 (100) 85,948 (100) 49,033 (100)
Table 2. Antimicrobial Resistant Rates (%) of S. aureus and Coagulase-Negative Staphylococcus Isolated in 2005 and in 2007
S. aureus* Coagulase-negative Staphylococcus�
Antimicrobial Hospital Commercial laboratory Hospital Commercial laboratory
agent 2005 2007 2005 2007 2005 2007 2005 2007
(n = 15,699) (n = 14,479) (n = 2,387) (n = 5,995) (n = 11,039) (n = 10,612) (n = 1,721) (n = 2,216)
Oxacillin 59 64 53 63 70 64 53 70
Penicillin 90 88 95 99 89 86 88 99
Clindamycin 52 52 43 56 34 29 22 30
Erythromycin 62 62 55 58 55 51 53 51
Cotrimoxazole 12 8 NT NT 31 27 NT NT
Tetracycline 45 47 45 47 34 28 33 31
Gentamicin 54 51 50 52 48 28 25 36
Fluoroquinolone 51 52 44 48 36 32 23 34
NT, not tested. 
*None of the isolates were resistant to teicoplanin or to vancomycin. 
�Less than 1% of the isolates were resistant to teicoplanin. 
vancomycin were very low, but those of E. faecium were
86% and 21%, respectively. In the ComLab, 42% of S.
pneumoniae were nonsusceptible to oxacillin, 86% of E.
faecium were resistant to ampicillin, and 17% of E. faeci-
um were resistant to vancomycin.
The resistance rates of E. coli in the hospitals to ampicil-
lin, cefotaxime, amikacin, and fluoroquinolone were 60%,
11%, 2%, and 27%, respectively (Table 4). In the ComLab,
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Table 4. Antimicrobial Resistance Rates (%) of E. coli and K. pneumoniae Isolated in 2005 and in 2007
E. coli K. pneumoniae
Antimicrobial Hospital Commercial laboratory Hospital Commercial laboratory
agent 2005 2007 2005 2007 2005 2007 2005 2007
(n = 16,075) (n = 15,690) (n = 5,609)(n = 13,596)(n = 8,936)(n = 8,117)(n = 2,086) (n = 5,955)
Ampicillin 65 60 69 70 -* - - -
Ampicillin-sulbactam 32 29 - 31 34 30 NT 47
Piperacillin 54 35 28 38 50 45 49 99
Piperacillin-tazobactam 3 2 1 1 14 12 5 7
Ticarcillin-clavulanate 11 12 14 5 28 23 39 22
Cephalothin 27 22 31 54 42 37 50 54
Cefotaxime 12 11 12 45 25 25 38 45
Ceftazidime 12 8 12 47 32 29 41 47
Aztreonam 10 11 NT 21 30 27 NT 44
Cefepime 10 8 11 20 19 22 31 44
Cefoperazone-sulbactam 4 3 NT NT 11 5 NT NT
Cefoxitin 8 6 8 11 24 21 33 35
Cefotetan 3 1 NT NT 12 9 NT NT
Imipenem 0.2 0 0 0 0.3 0 0 0
Meropenem 0.4 0 NT 0 0.8 0 NT 0
Amikacin 4 2 3 4 24 18 30 31
Gentamicin 25 25 27 32 26 22 33 31
Tobramycin 17 15 16 18 36 29 49 44
Fluoroquinolone 32 27 35 42 30 27 34 42
Cotrimoxazole 33 32 NT NT 25 21 NT NT
Tetracycline 53 45 54 53 27 22 20 19
NT, not tested.
*Antimicrobial agent not recommended for susceptibility testing of that particular organism. 
Table 3. Antimicrobial Resistant Rates (%) of S. pneumoniae, E. faecalis, and E. faecium Isolated in 2005 and in 2007  
Species Antimicrobial agent
Hospital Commercial laboratory
2005 (n = 1,868) 2007 (n = 1,818) 2005 (n = 219) 2007 (n = 743)
S. pneumoniae Oxacillin* 64 69 34 42
Erythromycin 62 67 72 70
E. faecalis Ampicillin 2 3 1 7
Tetracycline 75 77 87 NT
Fluoroquinolone 36 28 28 34
Teicoplanin 2 1 0 0
Vancomycin 2 1 0 1
E. faecium Ampicillin 85 86 85 86
Tetracycline 14 13 20 20
Fluoroquinolone 83 84 79 85
Teicoplanin 17 16 10 12
Vancomycin 20 21 12 17
NT, not tested.
*Screening test for penicillin-nonsusceptible isolates. 
the resistance rates of E. coli to ampicillin and amikacin
were similar to those in the hospitals, but the rates of resis-
tance to cefotaxime and to fluoroquinolone were higher:
45% and 42%, respectively. Of K. pneumoniae hospital
isolates, 29% were resistant to ceftazidime, 21% to cefoxi-
tin, 18% to amikacin, and 27% to fluoroquinolone (Table
4). In the ComLab, the resistance rates to ceftazidime,
cefoxitin, amikacin, and fluoroquinolone were higher than
those in the hospitals. ESBL-producing E. coli and K.
pneumoniae were tested by 21 and 20 hospitals, respecti-
vely. The mean proportion of ESBL-producing E. coli and
K. pneumoniae isolates was 12% and 29% in 2007, res-
pectively (data not shown). 
Of the Enterobacter cloacae hospital isolates, 30% were
resistant to ceftazidime, 8% to cefepime, 6% to amikacin,
and 10% to fluoroquinolone (Table 5). The resistance rates
of this organism in the ComLab to ceftazidime and cefe-
pime were slightly lower, whereas the rates of resistance to
amikacin and fluoroquinolone were similar between the
ComLab and hospitals. Of the Serratia marcescens isolates,
17% were ceftazidime-resistant, 10% were cefepime-
resistant, 12% were amikacin-resistant, and 10% were
fluoroquinolone-resistant (Table 5). In the ComLab, 7% of
S. marcescens isolates were resistant to ceftazidime, but
15% were resistant to cefotaxime. The rates of resistance
to amikacin and fluoroquinolone were similar, but resis-
tance to cefepime was lower in the ComLab isolates than
in the hospital isolates. 
Of P. aeruginosa hospitals isolates, 18% were resistant
to piperacillin-tazobactam, 19% to ceftazidime, 21% to
imipenem, 19% to amikacin, and 33% to fluoroquinolone
(Table 6). The resistance rates of the ComLab P. aeruginosa
isolates to piperacillin-tazobactam were similar to those of
the hospital isolates, but those to ceftazidime, imipenem,
amikacin, and fluoroquinolone were higher than those in
the hospitals. Of the Acinetobacter spp. hospitals isolates,
26% were resistant to ampicillin-sulbactam, 19% to cefo-
perazone-sulbactam, and 50% to ceftazidime. The imipe-
nem resistance rate was 22%, which was an increase from
16% in 2005. The resistance rates to amikacin and fluoro-
quinolone were 37% and 48%, respectively (Table 6). In
the ComLab, the resistance rates to ampicillin-sulbactam,
ceftazidime, and imipenem were similar, but that to amika-
cin was slightly lower and that to fluoroquinolone was
slightly higher than those in the hospitals. 
The numbers of hospitals that tested the susceptibility of
non-typhoidal Salmonella were 29 in 2005 and 33 in 2007.
The resistance rate of hospital isolates of this organism to
ampicillin, cotrimoxazole, and fluoroquinolone was 38%,
8%, and 0%, respectively. In the ComLab, the incidence of
isolates resistant to ampicillin was slightly lower (data not
shown). The susceptibility of Haemophilus influenzae was
tested by 18 hospitals in 2005 and 23 in 2007. Among
these hospitals 19 tested both ampicillin susceptibility and
KONSAR Surveillance Study 2005 and 2007
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Table 5. Antimicrobial Resistance Rates (%) of E. cloacae and S. marcescens Isolated in 2005 and in 2007
E. cloacae S. marcescens
Antimicrobial Hospitals Commercial laboratory Hospitals Commercial laboratory
agent 2005 2007 2005 2007 2005 2007 2005 2007
(n = 2,914) (n = 2,817) (n = 478) (n = 1,319) (n = 1,694)(n = 1,956) (n = 795) (n = 2,604)
Piperacillin 40 30 26 24 34 38 27 37
Piperacillin-tazobactam 13 9 4 3 10 8 2 1
Ticarcillin-clavulanate 31 27 23 17 24 22 24 NT
Cefotaxime 33 29 19 21 20 21 11 15
Ceftazidime 33 30 23 19 16 17 6 7
Aztreonam 29 27 NT 17 16 22 NT 9
Cefepime 9 8 1 4 10 10 NT 2
Cefoperazone-sulbactam 10 5 NT NT 7 10 NT NT
Imipenem 0.3 0 0 0 1 1 0 0
Meropenem 0.8 1 NT 0 3 1 NT 0
Amikacin 9 6 4 6 15 12 14 11
Gentamicin 20 17 20 18 30 34 40 40
Tobramycin 28 21 33 23 38 38 57 51
Fluoroquinolone 9 10 6 14 8 10 13 13
Cotrimoxazole 26 24 NT NT 18 19 NT NT
Tetracycline 26 20 22 21 78 52 58 40
NT, not tested. 
β-lactamase production, 19 tested ampicillin susceptibility
only, and 12 tested β-lactamase production only (data not
shown). Among the 2007 isolates, 56% were resistant to
ampicillin and 41% were β-lactamase positive (data not
shown). The resistance rate of this organism to cotrimox-
azole was 42%, which was lower than that the 56% ob-
served in 2005.  
Significant resistance trends
Temporal trends of important antimicrobial agent-organism
combinations in hospitals are shown in Figs. 1-4. In 2005,
the proportion of MRSA, penicillin-nonsusceptible S.
pneumoniae, and ampicillin-resistant E. faecium decreased
slightly relative to 2003, but in 2007, the proportion of these
organisms returned to the 2003 levels (Fig. 1). The propor-
tion of vancomycin-resistant E. faecium remained unchang-
ed from 2003 to 2005, while in 2007, the proportion was
approximately five-fold higher than that ten years prior. 
The rates of resistance of K. pneumoniae to ceftazidime,
fluoroquinolone, and amikacin increased significantly in
2005 compared to those of previous years and then decreas-
ed slightly in 2007 (Fig. 2). Cefoxitin resistance rates of
this organism remained largely unchanged since 1999.
Over the last decade, fluoroquinolone resistance increased
approximately four-fold, while amikacin resistance increas-
ed over two-fold. 
Fewer P. aeruginosa isolates were resistant to fluoroqui-
nolone and amikacin in 2007, but the rates of resistance to
these antibiotics remained high: 33% and 19%, respecti-
vely (Fig. 3). Ceftazidime and imipenem resistance incre-
ased gradually, reaching proportions of 19% and 21%,
respectively. Acinetobacter spp. showed decreased resis-
tance to ceftazidime, fluoroquinolone, and amikacin, but
the rates were still very high in 2007; 50%, 48%, and 37%,
Kyungwon Lee, et al.
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Table 6. Antimicrobial Resistance Rates (%) of Acinetobacter spp. and P. aeruginosa Isolated in 2005 and in 2007 
P. aeruginosa Acinetobacter spp.
Antimicrobial Hospitals Commercial laboratory Hospitals Commercial laboratory
agent 2005 2007 2005 2007 2005 2007 2005 2007
(n = 10,728) (n = 9,532) (n = 2,817) (n = 8,808) (n = 4,882)(n = 4,283) (n = 933) (n = 2,815)
Ampicillin-sulbactam -* - - - 29 26 NT 24
Piperacillin 29 24 30 34 52 46 58 56
Piperacillin-tazobactam 18 18 16 23 33 27 16 20
Ticarcillin-clavulanate 36 22 47 29 36 62 45 78
Cefotaxime 46 68 70 97 57 59 63 98
Ceftazidime 20 19 19 28 56 50 61 58
Aztreonam 23 22 21 29 67 62 75 78
Cefepime 20 22 19 29 45 44 30 43
Cefoperazone-sulbactam 23 26 NT NT 24 19 NT NT
Imipenem 19 21 19 29 16 22 9 20
Meropenem 19 16 20 25 29 24 16 23
Amikacin 22 19 29 30 43 37 32 25
Gentamicin 33 29 43 42 54 51 61 58
Tobramycin 30 26 43 40 54 43 60 51
Fluoroquinolone 34 33 49 51 51 48 66 64
Cotrimoxazole - - - - 52 52 NT NT
Tetracycline - - - - 62 70 51 98
NT, not tested.
*Antimicrobial agent not recommended for susceptibility testing of that particular organism.
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Fig. 1. The resistance trends of gram-positive cocci in the hospitals. Oxacillin-
resistant S. aureus, penicillin-nonsusceptible S. pneumoniae, and ampicillin-
resistant E. faecium continued to have high prevalence rates, and a gradual
increase in vancomycin-resistant E. faecium strains was observed. OXA,
oxacillin; PEN, penicillin; AMP, ampicillin; VAN, vancomycin; R, resistant; NS,
nonsusceptible; SAU, S. aureus; SPN, S. pneumoniae; EFM, E. faecium. 
respectively. Imipenem resistance increased 22-fold over
the past decade from 1% in 1997 to 22% in 2007 (Fig. 4).
Comparison of the resistance rates of antibiotic-organism
combinations of concern between hospitals and the ComLab
showed similar prevalences of MRSA (64% vs. 63%) and
ampicillin-resistant E. faecium (86% each). Penicillin-
nonsusceptible S. pneumoniae isolates were more preval-
ent in hospitals than in the ComLab (69% vs. 42%), vanco-
mycin-resistant E. faecium were slightly more prevalent
(21% vs. 17%), and proportions of imipenem-resistant
Acinetobacter spp. were similar (22% vs. 20%). More cefo-
taxime-resistant E. coli (45% vs. 11%), K. pneumoniae
(45% vs. 25%), and imipenem-resistant P. aeruginosa
(29% vs. 21%) were detected in the isolates analyzed by
the ComLab than were found in the hospital isolates.
Antimicrobial resistance rates can vary greatly among coun-
tries,16 hospitals, and even wards. For example, the European
Antimicrobial Resistance Surveillance System (EARSS)
Annual Report in 2008 (www.escmid.org) revealed that
the proportion of MRSA was only 1% in Sweden whereas
it was 53% in Portugal. In Portugal, the rate varied from 0%
to 89% depending on the laboratory. This highlights the
importance of a national surveillance program. To guide
clinicians in the empirical selection of an appropriate antimi-
crobial agents, use of the first patient isolate has been
recommended by the CLSI.17 However, a study showed that
not all participating U.S. hospitals followed this guidel-
ine.18 Resistance selection occurring within the observation
period cannot be detected when only the first isolates are
included.3 In contrast to previous surveillance studies,
hospitals with duplicate isolates were excluded in the pre-
sent study. Inclusion of only the first isolate may result in
slightly lower resistance rates, particularly for certain noso-
comial pathogens.19 
We found that E. coli, S. aureus, CNS, P. aeruginosa,
and K. pneumoniae, in rank order, were the five most pre-
valent organisms in hospitals in Korea in 2007, indicating
that these organisms were as important in 2007 as they
were in 2004 (Table 1). In Germany, hospitals with an
onsite microbiology laboratory reported higher frequencies
of health care-associated infections than did hospitals
without in-house laboratory services.4 This suggests that the
rank order of organisms in the ComLab may not be accurate. 
The most prevalent organisms isolated from ICU pati-
ents in 2000-2002 were S. aureus in the US, Canada, and
France, P. aeruginosa in Italy, and CNS in Germany.16 A
2006-2007 National Healthcare Safety Network (NHSN,
which includes the former National Nosocomial Infections
Surveillance) reported that the three most prevalent organi-
sms isolated from healthcare-associated infections (HAI)
were CNS (15%), S. aureus (15%), and Enterococcus sp.
(12%).20 This suggests that our isolates were mostly from
KONSAR Surveillance Study 2005 and 2007
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Fig. 2. The resistance trends of K. pneumoniae in the hospitals. The cefoxitin
resistance rate remained high but stable, whereas ceftazidime, fluoroquinolone,
and amikacin resistance rates increased in 2005 compared to those of previous
years. CAZ, ceftazidime; FOX, cefoxitin; FQN, fluoroquinolone; AMK, amikacin. 
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Fig. 4. The resistance trends of Acinetobacter spp. isolates in hospitals. The
resistance rates to ceftazidime, fluoroquinolone, and amikacin decreased
slightly, but that to imipenem increased steadily. FQN, fluoroquinolone; AMK,
amikacin; CAZ, ceftazidime; IPM, imipenem.
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Fig. 3. The resistance trends of P. aeruginosa isolates from hospitals. The
resistance rates to fluoroquinolone and amikacin declined slightly, but those to
ceftazidime and imipenem remained stable. FQN, fluoroquinolone; AMK,
amikacin; CAZ, ceftazidime; IPM, imipenem.
inpatients and hence had high resistance rates. A. bauman-
nii can easily acquire antibiotic resistance determinants.21
We therefore predicted that this organism would become
more prevalent, but it became less prevalent in the hospi-
tals, with a change in rank from the sixth position in 2004
to the eighth position in 2007. In the ComLab data, the
typical nosocomial nonfermentative pathogen P. aerugi-
nosa ranked second in 2007, as in 2004.6
The CLSI document17 recommends groups of antimi-
crobial agents for susceptibility testing. Group A agents
are recommended for primary testing and reporting, while
Group B contains agents that may warrant primary testing,
however, they should be reported only selectively, such as
when the organism is resistant to agents of the same family.
However, these recommendations are difficult to follow in
practice when resistant organisms are very prevalent.
When a laboratory tests only a few classes of antimicrobial
agents, information on other agents of interest to clinicians
is not available, resulting in potential misselection of antimi-
crobial agents. More laboratories used cephalothin, pipera-
cillin-tazobactam, and cefoxitin to test E. coli in 2007 than
in 2002, but still the laboratories using ampicillin-sulbactam
(or amoxicillin-clavulanic acid) and cefoxitin were only
65% and 81%, respectively. Only 51% and 61% of labora-
tories used cotrimoxazole to test for E. coli and S. aureus,
respectively.  
Certain antibiotic-organism combinations are relatively
more prevalent in Korea and other Asian countries than in
the rest of the world. The results of the present surveillance
study highlight the fact that MRSA continues to be preval-
ent in Korea, with an occurrence rate of 64% (Fig. 1). In a
nationwide surveillance study in Japan in 2007, 59.7% of
respiratory isolates of S. aureus were methicillin-resistant.22
Analysis of data from the Surveillance Network-USA
(TSN), an electronic surveillance network that collected
microbiology data from 300 clinical microbiology labora-
tories across the US, revealed that the proportions of MRSA
in 2005 in non-ICU inpatients, ICU patients, and outpati-
ents were 59.2%, 55%, and 47.9%, respectively.23 All of
the reports discussed above indicate that MRSA has also
become a serious problem in non-Asian countries.
The CLSI document17 defined two different penicillin G
susceptibility breakpoints for S. pneumoniae depending on
the site of isolation. The vast majority of S. pneumoniae
isolates are from non-meningitis patients. Therefore, apply-
ing meningitis breakpoint to all S. pneumoniae appears
illogical, but in epidemiologic surveillance studies, it was
suggested that continued reporting based on meningitis
(≤ 0.06 µg/mL) breakpoint might also be useful to allow
for continuity in the reporting of long-term resistance
occurrence data.24 These investigators reported that the
MIC range of penicillin for a large number of worldwide
isolates in 2006 was ≤ 0.03-32 µg/mL, but 68% of the
isolates were inhibited by ≤ 0.06 µg/mL, 93% by 2 µg/mL
(non-meningitis susceptible), and 99% by 4 µg/mL (non-
meningitis intermediate). In our previous surveillance study,
penicillin susceptibility testing was performed mostly
using the oxacillin disk test to screen nonsusceptible isola-
tes based on the meningitis breakpoint. In the current
study, penicillin-nonsusceptible S. pneumoniae remained
very prevalent (69%) in hospitals in 2007 (Fig. 5), but the
rate in the ComLab was much lower (42%) (Table 3). A
high prevalence of penicillin-nonsusceptible S. pneu-
moniae has also been reported in other Asian countries.25 
The resistance rates of E. faecalis to ampicillin and
vancomycin are very low. However, since 2003, the van-
Kyungwon Lee, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 6   November 2010908
Hospital
Re
si
st
an
ce
 (%
)
OXA-R 
SAU
64 63
0
20
40
60
80
100
ComLab
PEN-NS
SPN
69
42
AMP-R
EFM
86 86
VAN-R
EFM
21
17
CTX-R
ECO
11
45
CTX-R
KPN
25
45
IPM-R
ACI
22 20
IPM-R
PAE
21
29
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comycin resistance rate of E. faecium has been reported to
be 20% or higher in the hospitals (Fig. 5). The ComLab
rates of E. faecium vancomycin-resistance were 12% in
2005 and 17% in 2007 (Table 3); a significant increase
compared to 7% in 2003.26 Vancomycin-resistant E. fae-
cium has also become more prevalent in the United States.
In a Chicago Hospital, the prevalence of vancomycin-resis-
tant E. faecium increased from 28.9% in 1993 to 72.4% in
2002, based on one isolate per patient per month.27 The
NHSN report20 stated that among the isolates from catheter-
associated urinary tract infections and central line-associ-
ated bloodstream infections in 2006 and 2007, 90.4% and
80% of E. faecium were resistant to ampicillin and to van-
comycin, respectively. This indicates that vancomycin-
resistant enterococci are difficult to control. The rates of E.
faecium resistance to ampicillin were similar in the current
study and in the NHSN report, but vancomycin-resistance
was lower in our study than in the NHSN report. 
The prevalence of ampicillin-resistant E. coli in hospitals
was 60% in 2007, a slight decrease compared to the 2004
rate, but in the ComLab it was 70%. This finding indicates
that empirical selection for ampicillin is difficult, but that a
significant proportion of E. coli infections can be treated
using ampicillin after laboratory testing. E. coli and K.
pneumoniae often acquire ESBL genes. In 2007, 11% of
E. coli and 29% of K. pneumoniae hospital isolates were
resistant to cefotaxime or ceftazidime, respectively, sugge-
sting ESBL production. Some hospitals tested E. coli and
K. pneumoniae for both susceptibility to third-generation
cephalosporins and the production of β-lactamases. The
resistance rates to third-generation cephalosporins and
ESBL positive rates in 2007 were E. coli 12% and 12%, res-
pectively, and K. pneumoniae 32% and 27%, respectively.
It is of concern that in the ComLab in 2007, the ceftazi-
dime-resistance rates of both E. coli and K. pneumoniae
were much higher (47%) than those documented for hos-
pitals. An outbreak of SHV-12 type ESBL-producing K.
pneumoniae was recently reported in a Korean hospital.28
In the hospitals, 6% of E. coli and 21% of K. pneu-
moniae were resistant to cefoxitin, suggesting plasmid-
mediated AmpC production. A previous study showed that
the high prevalence of cefoxitin-resistant K. pneumoniae
isolates was due to the plasmid-mediated AmpC enzymes,
DHA-1 and CMY-1.10 It was reported that among the
isolates from the Asia-Pacific region in 1998-2004, 8.9%
of E. coli and 20.3% of K. pneumoniae isolates were ESBL
screen-positive, but significant proportions of them were
confirmation test negative.29 Among these nonconfirming
isolates, 62% of E. coli and 75% of K. pneumoniae har-
bored a plasmid-borne AmpC enzyme of the CIT or DHA
type. The high cefoxitin resistance rates of E. coli and K.
pneumoniae in our present study, 6% and 21%, respecti-
vely, indicate that ESBL detection could be difficult, result-
ing in underestimation of the prevalence. 
The percentages of ceftazidime-resistant E. cloacae and
S. marcescens isolates from the hospitals in 2007 were
30% and 17%, respectively; these values were slightly
lower than those reported in 2004, namely 35% and 23%,
respectively. The resistance rates to cefepime remained
low, and imipenem-resistant Enterobacteriaceae remained
very rare, but KPC type class A carbapenemase may emerge
in the near future in Korea. K. pneumoniae isolates produc-
ing KPC carbapenemase are commonly isolated in health
care institutions located in the Northeast US, but the resis-
tance has also spread to other parts of the country,30 as well
as to other counties, including China.31
The rates of ampicillin resistance and β-lactamase pro-
duction in H. influenzae were similar in 2004 (47% and
51%, respectively), but in 2007, the rates were 51% and
41%, respectively. It is necessary to determine whether this
difference is indeed due to the emergence of β-lactamase-
negative ampicillin-resistant (BNAR) H. influenzae, which
have become prevalent in Japan.32 The resistance rates of
non-typhoidal Salmonella to cotrimoxazole (8%) and fluo-
roquinolone (0%) in hospitals were similar to those in 2004,
but the ampicillin resistance rate decreased slightly from
44% to 38%. Fluoroquinolone resistance rate, despite
being as low as 0%, probably fails to indicate clinical effi-
cacy in the treatment of extraintestinal infections. This is
because low-level quinolone resistance cannot be detected
using fluoroquinolones.17
P. aeruginosa and Acinetobacter spp. are important
nosocomial pathogens. With the emergence of multidrug-
resistant isolates, few drugs are now available to treat
Acinetobacter infections. Polymyxins are the only thera-
peutic option in many cases,33 but the emergence of A.
baumannii isolates resistant to all tested antimicrobials,
including polymyxin B, have been reported in Korea.34
Fewer isolates of P. aeruginosa and Acinetobacter spp.
were resistant to fluoroquinolone and amikacin in our
study than has been documented previously. The rates of
imipenem resistance in P. aeruginosa remained stable, but
more Acinetobacter spp. isolates were impenem-resistant
than has been reported previously. It was shown that in P.
aeruginosa, only 10.8% of imipenem resistance was due to
metallo-β-lactamase production,8 but the majority of resis-
tance in Acinetobacter spp. was due to OXA-type carba-
penemase production.9 Outbreak of imipenem-resistant A.
baumannii with OXA-23 carbapenemase was recently
reported in a Korean tertiary care hospital.35 Increasing car-
bapenem resistance is a serious problem, because this is
the only class of β-lactam agents active against isolates
producing ESBLs or derepressed AmpC enzymes.36
In contrast to our predictions, third-generation cephalo-
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sporin-resistant E. coli and K. pneumoniae strains and
imipenem-resistant P. aeruginosa strains were more pre-
valent in isolates analyzed by the ComLab (Fig. 5) than in
isolates examined by the hospital laboratory, suggesting
that antimicrobial-resistant nosocomial pathogens are also
a serious problem at smaller hospitals and clinics that have
no in-house microbiology laboratory service. 
In conclusion, MRSA, third-generation cephalosporin-
resistant K. pneumoniae, and fluoroquinolone-resistant E.
coli, P. aeruginosa and Acinetobacter spp. are still pre-
valent in the hospitals, and the smaller hospitals and clinics
in Korea, and vancomycin-resistant E. faecium, and imipe-
nem-resistant Acinetobacter spp. have gradually increased
in Korean hospitals over the last decade. The higher pre-
valences of third-generation cephalosporin-resistant E. coli
and K. pneumoniae and imipenem-resistant P. aeruginosa
in ComLab isolates are of concern. 
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